Nutriband Inc. (NTRBW)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Nutriband Inc. (NTRB) Reports Q1 Loss, Misses Revenue Estimates
Nutriband Inc. (NTRB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.21 per share a year ago.
Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application
ORLANDO, FL / ACCESSWIRE / October 31, 2024 / Nutriband (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced that theChinese National Intellectual Property Administrant (CNIPA) has fully issued its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the Company's lead technology AVERSA™. The patent underpins 4p Therapeutics' abuse deterrent transdermal system, AVERSA, which uses taste aversion to address the primary routes of abuse for opioid based transdermal patches.
Nutriband Inc Mosquito Repellent Patch Approved by Ministry of Health of Costa Rica
The approved product will be exclusively distributed through Farmavision S.A. throughout Costa Rica ORLANDO, FL / ACCESSWIRE / October 17, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that it has received approval from the Costa Rica Ministry of Health for the production and marketing of its Mosquito Repellent Patch, designed to reduce the risk of mosquito bites and associated health risks associated with exposure to mosquito bites.
Nutriband Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BO Brian Oliveira Clear Street Group Inc. | 61,590 | $104,703 | $55,431 | -$49,272 | -47.06% |
Nutriband Inc. (NTRBW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Nutriband Inc. ever had a stock split?
Nutriband Inc. Profile
| Biotechnology Industry | Healthcare Sector | Gareth Sheridan CEO | NASDAQ (CM) Exchange | 67092M125 CUSIP |
| US Country | 3 Employees | - Last Dividend | 15 Aug 2022 Last Split | 1 Oct 2021 IPO Date |
Overview
Nutriband Inc., founded in 2016 and based in Orlando, Florida, specializes in the development of transdermal pharmaceutical products. Centered around innovative drug delivery systems, the company has dedicated itself to creating solutions that offer safer and more efficient ways to deliver medications through the skin, directly into the bloodstream. Its core mission revolves around leveraging its proprietary technologies to tackle the challenges in drug administration, particularly focusing on abuse prevention and improving medication compliance. Nutriband Inc. plays a significant role in the pharmaceutical industry by offering groundbreaking alternatives to traditional oral and injectable medications, aiming to improve patient outcomes in various therapeutic areas.
Products and Services
-
AVERSA fentanyl
This product stands as Nutriband Inc.'s flagship in development, representing an innovative approach to pain management. AVERSA fentanyl is a transdermal system designed for extended-release medication, specifically catered to individuals with chronic pain who require continuous opioid therapy. Its abuse-deterrent features mark a significant advancement in the safe administration of fentanyl, aiming to reduce the risks associated with opioid therapy.
-
AVERSA buprenorphine
Part of the company's broader AVERSA product line, this transdermal patch is being developed for those dealing with moderate to severe chronic pain. Buprenorphine, known for its lower risk of dependence compared to other opioids, is utilized here in a way that harnesses the benefits of transdermal drug delivery, providing steady pain relief while minimizing abuse potential.
-
AVERSA methylphenidate
This product under development targets individuals with ADHD, offering a novel transdermal delivery system for methylphenidate. AVERSA methylphenidate is aimed at enhancing patient compliance and minimizing abuse through steady medication release.
-
Exenatide for Type 2 Diabetes
Expanding its portfolio into the management of type 2 diabetes, Nutriband is working on a transdermal delivery system for exenatide, a medication that aids in controlling blood sugar levels. This product promises to offer an alternative to subcutaneous injections, potentially improving adherence and patient experience.
-
Follicle Stimulating Hormone for Infertility
Tapping into the treatment of infertility, the company is developing a transdermal system for the administration of follicle stimulating hormone (FSH). This approach aims to simplify the treatment process for infertility, making it less invasive and more accessible to patients eager for a less burdensome route to medication administration.
-
RAMBAM Closed System Transfer Devices
In collaboration with Rambam Med-Tech Ltd., Nutriband is engaged in the development of closed system transfer devices. These devices are designed to safely transfer medication from one container to another, reducing the risk of exposure to hazardous drugs, thereby ensuring protection for healthcare professionals and patients alike.
-
AVERSAL Fentanyl with Kindeva Drug Delivery, L.P.
This partnership with Kindeva Drug Delivery, L.P. is focused on the development of AVERSAL Fentanyl, utilizing Nutriband's proprietary AVERSAL abuse deterrent transdermal technology. This collaboration underscores the company's commitment to advancing safer opioid therapies through innovative drug delivery systems.
